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ABSTRACT
Triple Negative breast cancer (TNBC) is a subtype of breast cancer that lacks the 
expression of estrogen receptor (ER), progesterone receptor, and human epidermal 
growth factor receptor 2. TNBC accounts for 15-20% of all breast cancer cases but 
accounts for over 50% of mortality. We propose that Estrogen receptor-beta (ERβ) 
and IGF2 play a significant role in the pathogenesis of TNBCs, and could be important 
targets for future therapy.
Tissue microarrays (TMAs) from over 250 TNBC patients’ were analyzed for 
ERβ and IGF2 expression by immunohistochemistry. Expression was correlated with 
clinical outcomes. In addition, TNBC cell lines Caucasians (CA): MB-231/BT549 and 
African Americans (AAs): MB-468/HCC70/HCC1806 were used to investigate the 
effect of hormonal and growth factor regulation on cell proliferation.
TMAs from AAs had higher expression of ERβ and IGF2 expression when 
compared to CA. ERβ and IGF2 were found to be upregulated in our TNBC cell lines 
when compared to other cell types. TNBC cells treated with ERβ agonist displayed 
significant increase in cell proliferation and migration when compared to controls. AA 
tissue samples from TNBC patients had higher expression of ERβ. African-American 
breast cancer TNBC tissue samples from TNBC patients have higher expression of 
ERβ. In addition, TNBC cell lines were also found to express high levels of ERβ. 
IGF2 increased transcription of ERβ in TNBC cells. Understanding the mechanisms of 
IGF2/ERβ axis in TNBC tumors could provide an opportunity to target this aggressive 
subtype of breast cancer.
INTRODUCTION
Triple negative breast cancer (TNBC) is a subtype 
of breast cancer (BC) and is defined by the lack of 
expression of three receptors: the estrogen receptor (ER), 
progesterone receptor (PR), and the human epidermal 
growth factor receptor 2 (HER2) [1]. TNBC accounts for 
roughly 15% of all breast cancer cases but represents over 
50% of mortality seen in breast cancer [2-4]. Therefore, 
current endocrine and HER2-targeted therapies are not 
viable for TNBCs, and the only treatment option available 
is chemotherapy [2, 4-6]. Although, TNBC patients tend 
www.oncotarget.com                               Oncotarget, 2018, Vol. 9, (No. 74), pp: 33912-33930
           Research Paper
Oncotarget33913www.oncotarget.com
to have higher clinical response rates to chemotherapy, 
they also have higher rates of distant recurrence and a 
worse overall prognosis than women with other breast 
cancer subtypes [7, 8]. TNBC is associated with health 
disparity because it is more common in premenopausal 
women of color (African-American women (AA) and 
Hispanic women (HS)) than Caucasian American women 
(CA) [3, 9]. Population based studies show that AA 
women with TNBC have a higher incidence, disease 
stage, and metastasis than CA [10, 11]. Therefore finding 
a new molecular target and/or treatment is the upmost 
importance within this patient population and in women 
with breast cancer in general.
Estrogens promote progression of ER-alpha (ERα) 
positive cancers, effected by the binding of estradiol 
to ERα [12]. ERα is predominantly localized in the 
nucleus and positive staining by immunohistochemical 
(IHC) detection, helps plan patient management [13]. 
Recent reports have shown a second ER, ERβ, is 
expressed in TNBC [14, 15]. ERα and ERβ are encoded 
by two different genes but share 96% homology in the 
DNA-binding domain and 60% homology in the ligand 
binding domain of ERα. ERβ’s role in BC progression 
remains to be elucidated, however, some studies have 
shown ERβ positivity is a biomarker related to a more 
aggressive clinical outcome [15] and correlates with Ki-
67, a proliferation marker [14-16]. Early studies suggest 
ERβ levels are higher in BCs in AA as compared to CA, 
and may play a role in TNBC progression [17-20]. Several 
ERβ isoforms occur in BC, including ERβ1, ERβ2, ERβ4, 
and ERβ5. Only ERβ1 retains an intact ligand binding 
domain which makes it a preferred clinical target [21-23]. 
ERβ occurs in the nucleus and in the cytoplasm and can 
be activated by both genomic or indirectly by nongenomic 
pathways [21, 24-26]. Recent reports indicate that ERβ 
target genes are enriched in genes that regulate cell death/
survival, cell movement, cell development, growth and 
proliferation, as well as genes involved in the Wnt/β-
catenin and G1/S cell cycle phase checkpoint pathways 
[27-30]. Furthermore, the exact role of ERβ, especially 
when expressed alone is not well studied. The first priority 
is to identity new prognostic and therapeutic targets that 
can identity and treat TNBC. We predict that ERβ may be 
such a target in TNBC.
Emerging evidence indicates that metabolic 
factors, such as insulin-like growth factor (IGF-1 and 
IGF-2) pathways enhance the progression of BC [31-
37]. IGF-2 occurs in two forms, precursor (pIGF-2) and 
mature (mIGF-2) and plays a role in BC proliferation 
and inhibition of apoptosis [38-40]. Under normal 
conditions IGF-2 is bound and sequestered [41-44], but 
overexpression of IGF-2 is associated with increased BC 
formation [43, 45]. Most human cancers over express IGF-
1 receptor (IGF-1R) and IGF-2 is a known ligand for the 
respective receptor and can bind to IGF-2 receptor (IGF-
2R), which sequesters IGF-2 [31-33, 35, 40]. Disparities 
with IGF-2 expression is also apparent, with AA having 
higher expression when compared to CA and could 
contribute to clinical outcome [46]. IGF-2 is expressed 
both in the BC stromal and epithelial compartments, and 
corresponds with both stromal and epithelial BC cell 
proliferation [33] [47-50]. ER signaling pathways are 
reported to intersect with IGF pathways, with estrogen 
promoting increased BC production of IGF2 [32]. In this 
study, we predict ERβ and/or IGF-2 may be such targets 
in TNBC.
Here, we report our findings on the importance of 
ERβ expression in TNBC progression. We investigated 
ERβ expression in different patient subtypes of breast 
cancer along with a panel of TNBC cell lines. We 
performed immunoblotting, quantitative-real-time 
PCR (qPCR), cell proliferation, migration/invasion, 
enzyme-linked immunosorbent assay (ELISA), and 
apoptosis studies on cell lines when ERβ is activated 
and/or inhibited. ERβ activation or inhibition resulted in 
significant differences in protein expression, migration/
invasion, IGF2 expression, and apoptosis. This study 
also identified that the activation of ERβ activates the IR/
IGF-1R signaling pathway via IGF2. We also show that 
activation of ERβ activated the MAPK signaling pathway.
RESULTS
ERβ is associated with decrease in relapse-free 
survival in TNBC
The roles of ERβ in breast cancer, let alone TNBC 
development and progression are not clearly elucidated. 
A database was established using mRNA expression 
data downloaded from gene expression omnibus (GEO) 
(http://www.ncbi.nlm.nih.gov/geo/), the cancer genome 
Atlas (TCGA) (http://cancergenome.nih.gov/), European 
genome-phenome archive (EGA) (https://ega.crg.eu/), and 
PubMed (http://www.pubmed.com) repositories to identify 
datasets with published mRNA expression and clinical 
data. Kaplan–Meier survival analysis was performed to 
validate the prognostic value. We determined the relapse-
free survival (RFS) status between ERβ and TNBC, using 
the public database KMPlot [51, 52], which consisted of 
3,951 breast cancer patients. KMPlot were used because 
it is a database integrating mRNA expression data and 
clinical information derived from four independent 
datasets of breast cancer. It is an easy-to-use bioinformatic 
tool capable of performing survival analyses (Months) for 
the identification and validation of prognostic mRNAs 
in breast cancer, and it allows for a real-time analysis 
to evaluate the prognostic value of those mRNAs in 
breast cancer. When accounted for TNBC patients 
only (restricted analysis to subtype hormone receptor 
negative: ERα-, PR-, HER2-), high ERβ expression is 
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Figure 1: ERβ is associated with decrease relapse free survival in TNBC. mRNA level of ERβ in TNBC was obtained from a 
public database, KMPlot. Kaplan–Meier survival analysis was used to assess the association between ERβ level and relapse-free survival 
(RFS). (A) RFS in all TNBC between Low ERβ and High ERβ groups, (B) RFS in TNBC underwent chemotherapy (Chemo) between Low 
ERβ and High ERβ groups, and (C) RFS in TNBC with adjuvant chemotherapy (adj Chemo) between Low ERβ and High ERβ groups. 
Log-rank test was used to assess the statistical significance between the groups and P<0.05 was considered as significance.
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significantly correlated with lower overall RFS (P = 0.007) 
(Figure 1A). When patients were given chemotherapy as 
a whole (Figure 1B) or adjuvant chemotherapy (Figure 
1C), high ERβ expression is significantly correlated with 
lower relapse free survival (RFS) (P = 0.0315 and 0.0415 
respectively) and a trend with high ERβ expression is seen 
to coincide with lower distance metastasis free survival. 
These results suggest that high ERβ expression in TNBC 
patients might play a role in the progression of TNBC.
ERβ expression in breast cancer cell lines
We assessed ERβ expression in a panel of several 
breast cancer cell lines from our lab. The cell lines we 
have represent the major subtypes of breast cancer: 
Luminal A (MCF7, T47D), Luminal B (BT474), 
HER2+ (SKBR3), and TNBC (BT549, HCC38, HCC70, 
HCC1806, HCC1937, HS578T, MBA157, MBA231, 
MBA453, MBA468). Luminal A cell lines will were 
taken as controls. Under normal growth conditions (10% 
FBS with phenol red), when compared to luminal A cell 
lines, all TNBC cell lines had increased expression of ERβ 
(Figure 2A right). Quantification of the bands are shown in 
Figure 2A left. Quantification of cellular lines were used to 
select 5 TNBC cell lines that represents African-American 
ethnicity (HCC70, HCC1806, MBA468) and Caucasian 
ethnicity (MBA231, BT549) for further studies. Selected 
cell lines were then analyzed for ERβ mRNA expression 
under 2% charcoal dextran stripped FBS in phenol red 
free media. Our data showed that all of the TNBC cells 
have at least a two fold increase in ERβ mRNA expression 
(Figure 2B) when compared to MCF7 cells. The respective 
cell lysates were subjected to gel electrophoresis and 
immunoblotting with ERβ and ERα antibodies. Results are 
shown in Figure 2C. TNBC cells show higher ERβ gene 
and protein expression.
ERβ activation increases migration and invasion 
in TNBC cells
To determine the effect of ERβ activation on cell 
migration, a wound healing assay on the TNBC cell 
lines were performed. TNBC cell lines were treated with 
known estrogen receptor agonist and/or antagonist, 20nM 
Diarylpropionitrile (DPN, ERβ agonist) and 100nM 
4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]-
pyrimidin-3-yl]phenol (PHTPP, ERβ antagonist) alone [53, 
54]. TNBC cells were grown in 2-well inserts that gave 
a uniform scratch of 500μm in either control media (2% 
charcoal stripped FBS is phenol red free media), 20μM 
ERβ agonist (DPN), or 100μM ERβ antagonist (PHTPP). 
Images captured at 0, 4, 8, 12, and 24h after incubation 
using phase-contrast microscope. The rate of migration was 
measured by quantifying the total distance that the cells 
moved from the edge of the scratch toward the center of 
the scratch at 24h when compared to 0h. Activation of ERβ 
by DPN resulted in a significant increase in would closure 
in our TNBC cell lines (Figure 3A-3D). PHTPP treatment 
resulted in a significant decrease in wound closure in our 
MB468 (Figure 3D) and HCC1806 (Figure 3F) when 
compared to control. These results indicated that ERβ 
activation in TNBC cells results in increased cell migration.
We then wanted to investigate what role activation 
of ERβ on cellular invasion of TNBC cells. To determine 
the effect that ERβ may have on invasion, TNBC cells 
were grown in the Corning BioCoat Matrigel Invasion 
Chamber. Cells were treated with either DPN or PHTPP in 
the upper-chamber for 24 hours, and the cell invasion was 
measured. Cells were fixed, stained with crystal violet, 
and quantification of invaded cells was done. Treatment 
of DPN significantly increased invasion in all cell lines 
(P < 0.042) (Figure 4A-4E), except MB231 where we saw 
a significant decrease in invasion when treated with DPN 
(Figure 4B), and, similarly, the treatment with PHTPP 
significantly decreased cellular invasion of BT549 and 
HCC1806, respectively (P < 0.04, Figure 4B, 4E).
ERβ activation increases proliferation in TNBC cells
The data presented here shows that activation of 
ERβ is involved in the migration and invasion of TNBC 
cells. We then wanted to investigate the effect of ERβ 
activation on cellular proliferation. To determine the 
effect of the activation of ERβ on TNBC cells we treated 
TNBC cells with DPN, PHTPP, or both over a 3 day 
period. Cell proliferation was measured by CellTiter-Glo. 
Quantification of cell proliferation was then measured 
by relative luciferase units (RLU), and then normalized 
to control to get fold change. Proliferation rate of TNBC 
cells were compared to control (Luminal A – MCF7 cells). 
Under normal conditions over a three day period we saw 
that all TNBC cell lines had a significant increase, at 
least a 1.5fold, in cellular proliferation when compared 
to control MCF7 cells (Figure 5A). We saw the highest 
proliferation rates in mesenchymal-like TNBC cells 
(MB231/BT549) vs basal-like subtype except for MB-
468 cells. Next, we determined the proliferation rate over 
a three day period, when treated with either DPN and/or 
PHTPP. We saw that treatment with PHTPP significantly 
decreased cellular proliferation over a three day period and 
DPN treatment increased cellular proliferation (Figure 5B-
5F). When TNBC cell lines were treated with both agonist 
and antagonist returned proliferation back to control 
levels. This increase in cellular proliferation could be due 
to ERβ down regulation of cell cycle inhibitors p21 and 
p27kip (Figure 5I). This data highlights that ERβ promotes 
cell proliferation when expressed in TNBC.
ERβ activation upregulates IGF2 and the IR
Since previous data has shown that activation of 
ERβ resulted in increased proliferation of TNBC cell 
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lines, we then wanted to determine by what mechanism 
is ERβ regulating cell growth. When we treated our cell 
lines with DPN and/or PHTPP we saw an upregulation in 
IGF2 mRNA (Figure 6A) and IGF2 and insulin receptor 
(IR) protein expression by DPN (Figure 6B). TNBC cells 
treated with PHTPP resulted in decreased IGF2 protein 
expression (Figure 6C). When TNBC cell lines were 
treated with DPN or PHTPP, a significant increase in 
IGF2 secretion by DPN and a decrease in IGF2 secretion 
by PHTPP in TNBC cell lines (Figure 6D). We then 
looked at what pathways were activated by ERβ. The data 
showed that the MAPK pathway and the IR pathway were 
activated in HCC1806 when compared to MCF7 cells and 
growth inhibition by DPN seen in MCF7 was due to the 
Figure 2: ERβ is expressed in TNBC cell lines. (A) The indicated panel of breast cancer cell were maintained in growth media 
with 10% FBS and protein was extracted until the cells reach to 80% confluence. Western blot analyses were performed with ERα, ERβ1 
and HER2 antibodies and β-actin antibody was used for loading control (A-right). The western blot of ERβ1 was repeated 3 times and 
the bands intensities were adjusted to β-actin. The bar graph (A-left) showed the mean intensities from three independent bots and SD for 
the indicated cell lines. “*” indicated p<0.05 compared to the intensity from MCF-7 cells and determined by one-way ANOVA. (B) The 
indicated TNBC cells were grown in phenol red free media with 5% charcoal treated FBS until 80% confluence and RNA was extracted. 
RT-qPCR was performed with ERβ1 and ERβ2 primers and adjusted to GAPDH. The bar graph presented as fold changed of ERβ1 and 
ERβ2 levels in the indicated TNBC cells compared to MCF-7 cells. Each bar indicated mean±SD from three experiments. (C) The indicated 
TNBC cells were grown in phenol red media with 5% charcoal treated FBS until 80% confluence and protein was extracted. Western blot 
analyses with ERα and ERβ1 antibodies were performed and β-actin was used for loading control.
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inhibition of the cell cycle through p27kip (Figure 6E). 
This data highlights that activation of ERβ increases IGF2 
secretion that can then act on the IR/IGF1R signaling 
pathway to control cell growth.
Knockdown of ERβ results in decreased 
proliferation
We then wanted to determine what role 
knockdown of ERβ had on cellular proliferation. We 
used scrambled and three pools of siRNA towards 
ERβ. Figure 6F shows the knockdown efficiency 
with the scramble and three different pools of siRNA. 
We saw that each siRNA was able to knockdown 
ERβ in T47D cells (Figure 6C). The pooled siRNA 
were transfected in our TNBC cell lines and through 
western blot determined the effect of ERβ knockdown 
on protein expression. Knockdown of ERβ was able 
to downregulate Cyclin D1 (CD1), EGFR, and ERβ 
(Figure 6G). We then looked at cellular proliferation. 
Knockdown of ERβ had a significant decrease in 
cellular proliferation (Figure 6H). We then wanted to 
determine what role ERβ plays in apoptosis. Apoptosis 
was determined by measuring the uptake of annexin 
in control cells (untreated), compared to cells with 
ERβ knockdown. The stained cells were analyzed by 
flow cytometry. Images represent 4 independent flow 
cytometer runs. As shown in Figure 7A-7E, a significant 
increase in apoptosis was seen in ERβ knocked down 
cells (Figure 7).
Figure 3: Activation of ERβ increases migration of TNBC cells. The cells were seeded in 8.5cm3 dishes with a 2 well silicone 
insert and treated with or without DPN or PHTPP for 24 hrs as described in methods. The wound closure was monitored and images were 
taken and analyzed from three different rears for each conditions. The bar graphs for MB231 (A), MB468 (B), HCC70 (C) and HCC1806 
(D) presented as percentage wound closures (mean ±SD) for each conditions. P-values between the indicated conditions were determined 
by one-way ANOVA.
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Figure 4: Activation of ERβ increases invasion of TNBC cells. The cellswere plated in top chamber of matrigel invasion chamber 
in phenol red free media with or without DPN or PHTPP and bottom chamber was filled with medium containing CSFBS as described in 
methods. After 24 hrs number of cell invasion was assessed. The total numbers of invaded cells were counted from 4 independent areas for 
each conditions and all experiments were independently repeated three times. The bar graphs for MB231 (A) BT549 (B) MB468 (C) and 
HCC70 (D), HCC-1806 (E) showed invaded cell numbers (mean ±SD) under each conditions. P-values between the indicated conditions 
were determined by one-way ANOVA.
Oncotarget33919www.oncotarget.com
ERβ expression in clinical samples using tissue 
microarray
We have seen that through the public database that 
high ERβ expression is correlated with lower RFS, and 
in TNBC cell lines that activation of ERβ resulted in 
increased cellular proliferation, migration, and invasion. 
We then wanted to see ERβ expression in TNBC across 
ethnicity. The make-up of our patient population is located 
in Table 1. As illustrated in Figure 8A, we had archival 
TNBC tissue specimens from Asian (AS, commercially 
purchased from US Biomax), African-American (AA), 
Hispanic (His), and Caucasian (CA) samples from the 
patient cohort in South Los Angeles. When compared 
to AS, AA and His patients had higher ERβ and IGF2 
expression (Figure 8A and Table 2). When separated by 
tumor type, both ERβ (Figure 8B) and IGF2 (Figure 8C) 
are expressed in similar levels within TNBC and Lum A 
cancers. When separated by race, looking at TNBC only, 
we see that ERβ and IGF2 are expressed significantly 
higher in AA and His when compared to CA (P < 0.02) 
(Figure 8D). We then looked at the association between 
ERβ and IGF2 and saw that, within TNBC, IGF2 and ERβ 
expression correlated with each other (Figure 8E) and 
that IGF2 was associated with increased ERβ expression 
(Table 3). This data highlights that African American and 
Figure 5: Activation of ERβ increases cell proliferation. The cells were treated with or without DPN, PHTPP, or DPN+PHTPP for 
3 days and cell proliferation was measured by The CellTiter-Glo® Luminescent Cell Viability Assay as described in methods. Proliferation 
rate of different TNBC cells without treatment (A), MB231 (B), BT549 (C) MB468 (D) HCC70 (E) and HCC1806 (F) cells with and 
without treated with DPN, PHTPP and DPN+PHTPP were determined by compared to MCF7 cells. The bar graphs indicated the mean fold-
changes with SD from 3 independent measurements and each measurements contained 6 repeated values for each condition. The p-values 
were determined by One-Way ANOVA (*P < 0.01, **P < 0.001, ***P < 0.0009, ****P < 0.0001). (G) HCC70 cells were treated with DNP for 
the indicated time and protein was extracted. Western blot analysis was performed with p21 and p27kip antibodies and β-actin was used as 
loading control.
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Figure 6: Activation of ERβ upregulates IGF2 and activates the IR/IGF1R/MAPK pathways. (A) The indicated cells 
were treated with or without DPN. mRNA level of IGF2 was determined by RT-qPCR and adjusted for GAPDH. The bar graph presented 
fold changes of IGF2 level in cells treated with DPN compared to non-treated cells (control). Each bar indicated mean ±SD from 3 
measurements and “*” indicated p<0.05 determined by one-way ANOVA. (B) Total protein was extracted from the indicated cells treated 
with or without DPN. Western blot analysis was performed with antibodies for IGF2, insulin receptor (IR) and IGFIR. β-actin was used 
for loading control. (C) The cells were treated with or without DPN, PHTPP or DPN+PHTPP as descripted in methods and total protein 
was extracted. Protein levels of ERβ1, IGF2 and IGFIR were determined by Western Blot analysis and β-actin was used as loading control. 
(D) The cells were maintained in serum free media and treated with or without DPN or PHTPP. Secreted protein level of IGF2 in the 
media was measured by IGF2 ELISA kit according to manufacture instruction as described in methods. The bars indicated mean level of 
IGF2 with SD from duplicated measurements and “*” indicated P<0.05 for the differences in level of IGF2 between the indicated cells and 
MCF7 cells determined by one-way ANOVA. (E) The cells were treated with DPN from 0 to 30 min and protein was extracted. Western 
blot analysis was performed with antibodies for P-ERK1/2, ERK1/2, P-p38, p38 and p27kip. β-actin was used as loading control. The level 
of P-ERK1/2 was further quantified with β-actin and showed under membrane of P-ERK1/2. (F) T47D cells were treated with 3 different 
siRNA sequences of ERβ and ERβ1 expression was determined Western Blot analysis with antibody for ERβ1 was used to assess efficiency 
of the siRNAs. (G) The cells were treated with pooled siRNA sequences for ERβ and the level of ERβ was determined by Western blot. The 
protein levels of cyclin D1 (CD1) and EGFR were also determined by Western blot analysis. β-actin was used as loading control. (H) The 
cells were treated with or without siRNA for ERβ and cell proliferation was determined by The CellTiter-Glo® Luminescent Cell Viability 
Assay as described in methods. The bars indicated fold changes (mena ±SD) of cells treated with siRNA compared to cells without treating 
with siRNA (control). “**” indicated P<0.001 between the indicated groups determined by one-way ANOVA.
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Hispanic patients with TNBC had higher ERβ and IGF2 
expression. This co-expression may result in decreased 
overall survival of TNBC patients.
DISCUSSION
Breast cancer patients who are presented with 
TNBC are frequently diagnosed at an advance stage of 
the disease, with high histologic grade, and are associated 
with a significantly higher probability of relapse and 
metastasis. This clinical diagnosis is as a health disparity, 
and currently, the most common treatment is systemic 
chemotherapy [3-11]. Discovery and higher expression 
of ERβ made it a logical therapeutic target because of its 
expression in TNBC and its structural similarity to ERα 
[13-15], however there have been conflicting results, 
some suggesting that ERβ is of favorable prognostic value 
[20, 55, 56], no prognostic value [57], or worse prognosis 
[16, 30, 58]. Some of the discrepancies can also be due to 
the fact that TNBC is a heterogeneous disease, and most 
studies that look at TNBC used the more accessible TNBC 
cell lines (MB231 and Hs578T) and did not account for 
the heterogeneity of TNBC. There are four subclasses of 
TNBCs [59] such as basal-like (BL) [7], mesenchymal 
Figure 7: Knockdown of ERβ results in increased apoptosis. TNBC cells were knockdown for ERβ and then subjected to flow 
cytometer as described in methods Representative images of flow cytometry data were presented. Percentage of apoptotic cells in (A) 
MB231, (B) BT-549, (C) MB-468, (D) HCC-70, and (E) HCC-1806 were showed in bar graphs as mean ±SD. The statistical differences 
between the indicated groups were determined by paired t-test.
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Figure 8: ERβ is expressed in breast cancer patients’ tissue microarray. (A) Immunohistochemical (IHC) analysis was used 
to determine ERβ1 and IGF2 expression in breast cancer primary tissues as described in methods. Represented images from IHC of H&E, 
ERβ1 and IGF2 in TNBC from Asian (AS), African American (AA), and Hispanic/Latina (His) patients were shown. (B and C) Bar graphs 
showed quantified IHC data of ERβ1 (B) and IGF2 (C) expression in different subtypes of breast cancer. The bars indicated percentage of 
positive staining for ERβ1 or IGF2 (mean ±SD) in the indicated subtype of breast cancers. (D) IHC data of ERβ1 was quantified and the 
bars indicated percentage positive expression of ERβ1 in the indicated racial ethnicities. (E) The correlation between expressing ERβ and 
IGF2 in patients was evaluated by Bivariate Correlations with two tailed test, performed with SPSS v.22.
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(MS) [60], immune-enriched (IM) [7, 61], and the luminal 
AR subtype (LAR) [61]. Others have suggested that the 
discrepancy may be due to a lack of standardized detection 
methods, poorly validated antibodies, inconsistent 
cutoffs for defining ERβ positive cancers via IHC, and 
variable tissue preparation and processing methods [62, 
63]. To address these discrepancies we used validated 
TNBC specimens (Negative for ERα. PR, and HER2 
overexpression). We used validated ERβ antibodies [30, 
63, 64], TNBC subtypes (BL1/2, MS, and MSL), and 
different ethnicities (AA: MB468 HCC-70/1806 CA: 
MCF7 T-47D, MB-231, BT-549).
Here we examined the role ERβ in disease 
progression, proliferation, invasion, and migration of 
TNBC. Our findings show that contrary to previous 
studies, ERβ activation is pro-tumorigenic in vitro. The 
relationship between the expression of ERβ and breast 
cancer clinical progression has been ambiguous, in 
the publically available data. TNBCs reviewed for our 
study have shown that high ERβ expression results in 
significantly lower RFS with or without chemotherapy. 
We have also shown that in TNBC cell lines that activation 
of ERβ results in increased secretion of IGF2 which 
can bind to IR/IGF1R, and activate growth promoting 
capabilities. Recent studies have shown that targeting the 
IGF1R pathway could be a therapeutic target [65, 66]. 
These results and the previous data suggest that endocrine 
therapy may be beneficial for improving TNBC outcomes.
ERβ has been suggested to control a myriad of 
functions in BC. Here we have shown that in most TNBC 
cells, activation of ERβ by DPN significantly increased 
cell invasion and migration, especially in cells that aren’t 
highly invasive (MB468, HCC-70/1806). However, 
in MB-231 cells, DPN caused significant decrease in 
cellular invasion. This discrepancy could be due to the 
that fact that a recent study [67] had shown that MB-
231 cells express androgen receptor (AR) and that in AR 
positive TNBC cells, ERβ decreases cellular invasion 
and migration. Another discrepancy could be due to 
the fact that these authors used an over-expressing ERβ 
construct, used FBS and phenol red containing media to 
determine invasion instead of using hormonal free FBS/
phenol red free media. In our study we used a specific 
agonist to activate ERβ expression, DPN. Even though 
our results corroborated on the decreased invasion by 
the activation of ERβ in MB-231 cells, the inhibition of 
migration (wound closure) due to ERβ activation didn’t 
agree. Also, we saw in another MS subtype, BT-549, that 
ERβ activation increased cellular invasion. This supports 
the notion that in specific subtypes of TNBC ERβ could 
have different effects.
In this study we also wanted to look at what pathways 
are activated by ERβ. In our ERα+ cell lines (MCF7, 
T47D) ERβ activation results in the increase expression of 
p21WAF/CIP1 and p27kip indicating that in ERα+ cell lines, ERβ 
provides and anti-proliferative role and agrees with overall 
Table 1: Subjects in CDU TMA
N (%)
Total 204
Ethnicity
African American 50 (24.5)
Hispanic 28 (13.7)
Asian 126 (61.8)
Age (yr)
<50 90 (44.1)
≥50 114 (55.9)
ERα/PR status
Positive 130 (63.7)
Negative 74 (36.3)
HER2 status
Positive (IHC 3+/FISH amplified) 52 (25.5)
Negative 152 (74.5)
Subtype (by receptors)
ERα/PR+/HER2- 104 (51.0)
HER2+ 52 (25.5)
TNBC 48 (23.5)
Tumor size
≤ 2cm 45 (22.1)
2cm – 5cm 115 (56.4)
> 5cm 32 (15.7)
Unknown 12 (5.9)
Node
Negative 68 (33.3)
Positive 127 (62.3)
Unknown 9 (4.4)
Stage
0-II 134 (65.7)
III-IV 66 (32.4)
unknown 4 (2.0)
ERβ (nuclear)
Positive 121 (59.3)
Negative 83 (40.7)
IGF2
IGF2-positive 41 (19.7)
IGF2-negative 159 (76.4)
missing 8 (3.8)
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BC RFS and other studies showing the anti-proliferative 
role of ERβ in ERα+ tumors [14-16, 20, 68, 69]. Cyclin–
CdK activity is regulated by phosphorylation events and 
cyclin kinase inhibitors, inhibit their activity. Our results 
showed that the upregulation of p21/27 might be one of 
the possible mechanisms of proliferation inhibition by 
ERβ in ERα+ tumors and the lack of activation of these 
inhibitors in TNBC. In TNBC, the activation of phospho-
ERK1/2, p38, SAPK/JNK, and PI3K which are involved 
in the MAPK and PI3K signaling pathways. This supports 
Table 2: ERβ and IGF2 status by ethnicity, age, tumor pathology and stage
N (%)
Total 204 ERβ-positive ERβ-negative p-Value IGF2-Positive IGF2-negative P-Value
Ethnicity
African American 50 (24.5) 36 (72.0) 14 (28.0) 26 (55.3) 21 (44.7)
Hispanic 28 (13.7) 18 (64.3) 10 (35.7) 11 (40.7) 16 (59.3)
Asian 126 (61.8) 67 (53.2) 59 (46.8) 0.019 4 (3.2) 122 (96.8) <0.001
Age (yr)
<50 90 (44.1) 52 (57.8) 38 (42.2) 21 (23.9) 67 (76.1)
≥50 114 (55.9) 69 (60.5) 45 (39.5) 0.774 20 (17.9) 92 (82.1) 0.378
ERα/PR status
Positive 130 (63.7) 81 (62.3) 49 (37.7) 26 (20.3) 102 (79.7)
Negative 74 (36.3) 40 (54.1) 34 (45.9) 0.3 15 (20.8) 57 (79.2) 1.0
HER2 status
Positive 52 (25.5) 26 (50.0) 26 (50.0) 7 (14.0) 43 (86.0)
Negative 152 (74.5) 95 (62.5) 57 (37.5) 0.141 34 (22.7) 116 (77.3) 0.228
Subtype
ERα/PR+/HER2- 104 (51.0) 69 (66.3) 35 (33.7) 23 (22.3) 80 (77.7)
HER2+ 52 (25.5) 26 (50.0) 26 (50.0) 7 (14.0) 43 (86.0)
TNBC 48 (23.5) 26 (54.2) 22 (45.8) 0.089 11 (23.4) 36 (76.6) 0.912
Tumor size
≤ 2cm 45 (22.1) 29 (64.4) 16 (35.6) 12 (27.3) 32 (72.7)
2cm – 5cm 115 (56.4) 63 (54.8) 52 (45.2) 11 (9.7) 102 (90.3)
> 5cm 32 (15.7) 23 (71.9) 9 (28.1) 0.677 14 (43.8) 18 (56.3) 0.208
Node
Negative 68 (33.3) 44 (64.7) 24 (35.3) 15 (22.4) 52 (77.6)
Positive 127 (62.3) 74 (58.3) 53 (41.7) 0.443 23 (18.4) 102 (81.6) 0.570
Stage
0-II 134 (65.7) 79 (59.0) 55 (41.0) 27 (20.6) 104 (79.4)
III-IV 66 (32.4) 41 (62.1) 25 (37.9) 0.759 13 (19.7) 53 (80.3) 1.0
Table 3: Association between expressing IGF2 and ERβ
IGF2 Status P-Value
High Low
ERβ-positive 32 (78%) 87 (54.7)
ERβ-negative 9 (22.0) 72 (45.3) 0.07
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previous studies that activation of ERβ resulted in the 
activation of MAPK/PI3K signaling [70, 71]. Knocked 
down (siRNA)/inhibited ERβ by a specific ERβ antagonist 
(PHTPP) saw a down regulation in Cyclin D1, EGFR, 
and MAPK/PI3K signaling, indicating ERβ roles in cell 
cycle and MAPK/PI3K signaling. We have also shown that 
down regulation of ERβ increase apoptosis in TNBC cell 
lines. Further studies are warranted to identify the precise 
mechanism by which ERβ overexpression can repress 
apoptosis in TNBC tumors.
In conclusion, the results of this study indicates 
that expression ERβ in TNBC patients is significantly 
associated with decreased RFS and RFS with/without 
chemotherapy. ERβ and IGF2 expression is positively 
correlated with each other, ERβ/IGF2 expression is 
increased in AA/HS women when compared to CA and 
AS. ERβ activation significantly increases invasion, 
migration, proliferation, and IGF2 secretion. When 
silencing ERβ or using a specific ERβ antagonist, we 
demonstrated that ERβ suppression resulted in decreased 
IGF2 secretion and proliferation. This suppression 
could possibly be due to the suppression of the MAPK/
PI3K/AKT pathways and IGF2 activation on IR/IGF-
1R. This work further highlights the roles ERβ plays 
in the heterogeneity of TNBC and can lead us to more 
promising therapeutics to specifically target ERβ or use 
combinational targets for ERβ, IR/IGF-1R, MAPK/PI3K/
AKT pathway signaling.
MATERIALS AND METHODS
Patients
Patients were selected from an ongoing breast 
cancer study conducted in the Division of Cancer Research 
and Training at Charles R. Drew University of Medicine 
and Science in South Los Angeles. Women were informed 
and consented from Martin Luther King Ambulatory Care 
Center (MACC) between 1995 and 2007. This study was 
approved by the Charles R. Drew University of Science 
and Medicine Institutional Review Board and written 
informed consent was obtained from all participants 
(Approval 00-06-041-13). A total 1400 participants have 
been consented into the study, and 370 subjects have 
breast cancer confirmed by surgical biopsy/pathology and 
follow-up data. Characteristics of tissue microarray are 
found in Table 1. Charles R. Drew University breast cancer 
patient tissue microarray contains African-American (AA) 
and Hispanic (His) breast cancer tissue. Asian (AS) tissue 
microarray came from US Biomax.
Definition of breast cancer subtypes
The receptor subtypes were categorized in the 
following manner: (a) Luminal A (LumA) (ER+ and/
or PR+) and HER2-, (b) LumB (ER+ and/or PR+) and 
HER2+, (c) and HER2+, and (d) triple negative (TNBC) 
(ER-/PR-/HER2-) based on immunohistochemistry 
(IHC) analysis. The ER/PR, HER2, and Ki67 status were 
obtained from the patient’s pathology reports. HR+ was 
defined as >5% nuclear positive for ER and/or PR in 
tumor cells. HER2+ was defined as HER2 3+ by IHC and/
or more than 2.2 HER2 genes counted for every copy of 
chromosome 17 (HER2/CEP17 ratio) by FISH analysis. 
Ki67 Low was defined as <= 20% nuclear positive, and 
Ki67 High was defined as > 20% nuclear positive. Asian 
patient tissue microarray was obtained from US Bio 
Max, Inc (Rockville, MD). Staining and receptor status 
are located on manufactures web page, sample: HBre-
Duc140Sur-01 (https://www.biomax.us/tissue-arrays/
Breast/HBre-Duc140Sur-01).
Cells, reagents, and antibodies
Triple negative breast cancer cells (TNBC; MDA-
MB-231/468, BT-649,) and ER/PR positive breast cancer 
cells (MCF7 and T-47D) were cultured in DMEM/F12 
(Gibco, Grand Island, NY), 10% fetal bovine serum 
(Gibco), and 1% penicillin/streptomycin (Gibco). Triple 
negative cell lines HCC 70/1806 were cultured in RPMI 
1640 (Gibco), 10% FBS (Gibco), or 5% dextran-coated 
charcoal-stripped FBS (CSFBS) (GE Life Sciences 
Pittsburgh, PA), and 1% penicillin/streptomycin (Gibco). 
Primary antibodies against ERβ1 (clone PPG5/10) were 
purchased from BioRad(AbDSerotec) (Valencia, CA), 
Insulin Receptor (Abcam) IGF2 from ThermoFisher 
(Rockford, IL), CNND1, EGFR, ERα, Beta-Actin from 
Santa Cruz Biotechnology (Santa Cruz, CA), p-ERK1/2, 
p-p38, p27, p21 from Cell signaling (Beverly, MA). 
ERβ agonist, Diarylpropionitrile (DPN) and antagonist, 
4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]-
pyrimidin-3-yl]phenol (PHTPP) were purchased from 
Tocris.
Cell migration test
TNBC cells were seeded in 8.5cm3 dishes and 
cultured in culture-insert 2 wells from Ibidi (Munich, 
Germany) to give a uniform scratch at 500μM. A line 
was created by removing the culture insert. Cells were 
then treated with DPN or PHTPP for 24hrs and pictures 
were taken at 0, 2, 4, 8, 12, and 24hr. The wound area 
was marked and cell migration into the scratched area was 
daily photographed using an inverted microscope.
Cell invasion assay
One day prior to beginning the assay, TNBC cells 
were starved in a serum-free medium in top chamber of 
Corning BioCoat matrigel invasion chamber with 8.0mm 
PET membrane (Corning Corning, NY). Invasion assay 
was performed using the matrigel invasion assay kit. 
Briefly, top chamber was plated with 5 × 104 cells in 
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serum-free, phenol red free medium with either 20mM 
DPN or 100mM PHTPP. Bottom chamber was filled 
with medium containing CSFBS and incubated at 37°C 
with 5% CO2 for 24 hours. After the fixation of cells to 
the bottom chamber, the upper chamber was removed of 
all cells, and then coated with crystal violet for 15mins. 
Chamber was then wash and analyzed for cell invasion 
by the detection of crystal violet positive cells on the 
bottom chamber. The total numbers of invaded cells 
were counted by hand in 4 independent sections. All 
experiments were independently repeated at least three 
times.
Apoptosis assay
Measurement of apoptosis was done by using 
Mitochondrial Membrane Potential Apoptosis Kit, with 
Mitotracker™ Red & Annexin V Alexa Fluor™ 488, for 
flow cytometry per manufacture protocol by Thermofisher. 
Cells were stained and then analyze the cells by flow 
cytometry, measuring the fluorescence emission at 
530 nm and 585 nm. The cells should resolve into two 
principal populations: live cells with a low level of green 
fluorescence and high red fluorescence, and apoptotic cells 
with moderate level of green fluorescence and low red 
fluorescence by our Attune NxT Flow Cytometer.
Transfection assay
ERβ si/shRNA was purchased from Santa Cruz 
Biotechnology. The transfection was performed on the 
Lonza 4D-Nucleofector™ System per manufacture 
protocol.
Cell viability assay
Cell viability assay was performed using CellTiter-
Glo (Promega) according to manufacturer’s instructions. 
TNBC and control cells were seeded at 2,000 cells/well in 
a 96-well plate, grown over 3 and 5 days in the presence 
and absence of DMSO, DPN, and PHTPP. CellTiter-Glo 
measurements were taken at several time points to track 
cell survival.
Quantitative-real-time PCR, western blot and 
IHC
For quantitative real-time PCR (qPCR) RNA 
was extracted with Trizol (Ambion) from 46 Surgical 
BPH and 53 Incidental BPH specimens. Subsequently, 
500 ng RNA was reverse transcribed into cDNA using 
iScript cDNA Synthesis Kit (BioRad, Valencia, CA). 
qPCR was performed using IQ SYBR Green Supermix 
(BioRad, Hercules, CA) and results were analyzed 
using BioRad CFX manager software. All results were 
calculated using ΔΔCt analysis and normalized to 
GAPDH expression.
For Western blotting, protein was extracted with 2% 
SDS buffer and 25 μg protein was run on pre-made 4-12% 
polyacrylamide gels (Life Technologies). Primary antibodies 
were incubated in 5% BSA in TBST for 1 hour or overnight 
or at 4°C followed by incubation in secondary antibodies and 
development using ECL. Membranes were stripped and re-
probed with an antibody against β-actin (Sigma).
Immunohistochemistry was performed as previously 
described [72] Briefly, 5 μm sections were de-waxed, 
rehydrated and endogenous peroxidases were blocked with 
hydrogen peroxide. Sections were then boiled in citrate 
and blocked in 5% serum for 1 hr. Primary antibodies were 
incubated overnight at 4°C at the following concentrations: 
ERb (1:100) and IGF2 (1:200). Biotinylated anti-mouse 
or -rabbit secondary antibodies (DAKO Carpentaria, 
CA) were incubated for 60 min at room temperature after 
slides were washed for 1 hr in PBS. Slides were incubated 
in ABC-HRP complex (Vector Laboratories Burlingame, 
CA) for 30 min. Bound antibodies were then visualized by 
incubation with 3,3′ diaminobenzidine tetrahydrochloride 
(liquid DAB, DAKO). Slides were then rinsed in tap 
water, counterstained with hematoxylin, and mounted.
Statistical analysis
Log-rank (Mantel-Cox) test was used to determine 
overall survival and relapse free survival between High 
and low ER-β gene expression. Mann–Whitney tests were 
used for univariate comparisons of study characteristics 
between two groups. A two-sided P-value of 0.05 or 
less was considered statistically significant. A two-way 
ANOVA test was used for comparisons of characteristics. 
Correlation between IGF2 and ER-β was evaluated by 
the determination of the Spearman correlation coefficient 
(GraphPad Prism).
Abbreviations
AA: African-American women, AR: androgen 
receptor, BC: Breast Cancer, CA: Caucasian American 
women, DPN: Diarylpropionitrile, ELISA: enzyme-linked 
immunosorbent assay, ER: Estrogen Receptor, ERα: ER-
alpha, ERβ: ER-beta, HER2: Human Epidermal Growth 
Factor Receptor 2, HS: Hispanic women, IGF: insulin-like 
growth factor (IGF-1 and IGF-2), IGF-1R: IGF-1 receptor, 
IGF2R: IGF-2 receptor, IHC: immunohistochemical, 
LAR: luminal AR subtype, mIGF2: mature IGF2, PHTPP: 
4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]-
pyrimidin-3-yl]phenol, pIGF2: precursor IGF2, PR: 
Progesterone Receptor, qPCR: quantitative-real-time PCR, 
TNBC: Triple negative breast cancer.
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